Experts Anticipate Second-generation Weight-loss Drugs

May 4, 2020
Grace Halsey
Grace Halsey

Patients with obesity may require long-term pharmacologic management to sustain weight loss. Obesity expert Donna Ryan, MD, talks about new drugs in the pipeline.

Patients with obesity, like those with chronic illnesses such as hypertension, require long-term phamracologic treatment to maintain weight loss, according to Donna Ryan, MD, current president of the World Obesity Federation and associate editor of the journal Obesity. She notes in this short video that current weight-loss drugs help sustain reductions of approximately 10%. Agents in the pipeline may reliably increase that to 15%--a level where important metabolic change begins.

Dr Ryan is professor emerita at the Pennington Biomedical Research Center at Louisiana State University and well-known obeisty researcher.

She has been an investigator for various US National Institutes of Health-sponsored studies, including Pounds Lost, DASH (Dietary Approaches to Stop Hypertension), DPP (Diabetes Prevention Program) and the Look AHEAD study. Dr. Ryan’s continuing interests focus on translation of effective weight management into primary care practices.

Other Patient Care videos featuring Dr Ryan

Opening the Obesity Conversation in Primary Care

Weight Reduction Risk While Sheltering in Place

Obesity and COVID-19: Very Dangerous Together

Weight Loss is not about Achieving an "Ideal"